A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3583-3588

  Syrigos, Konstantinos N ^a   Michalaki, B ^a   Alevyzaki, F ^a   Machairas, A ^a   Mandrekas, D ^a   Kindilidis, K ^a   Karatzas, G ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Docetaxel; Liposomal doxorubicin; Pancreatic cancer

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DEXAMETHASONE; DIPYRIDAMOLE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LIPOSOME; MITOMYCIN; NARCOTIC AGENT; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 0036875145     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M and Block GE: Experience with 647 consecutive tumors of the duodenum, ampulla, head of pancreas and distal common bile duct. Ann Surg 210: 544-553, 1989.
2. David AK, Vaughn DJ, Holroyde CP, Armstead B and Haller DG: A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial. Am J Clin Oncol 23: 37-9, 2000.
3. Nadler SH and Moore GE: A clinical study of fluorouracil. Surg Gynecol Obstet 127: 1210-4, 1968.
4. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF, Chitambar C and Anderson T: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 15; 65: 2207-12, 1990.
5. Hansen R, Quebbeman E, Ritch P, Chitambar C and Anderson T: Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 295: 91-3, 1988.
6. DeCaprio JA, Mayer RJ, Gonin R and Arbuck SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 9: 2128-33, 1991.
7. Rothman H, Cantrell JE Jr, Lokich J, Difino S, Harvey J, Ahlgren J and Fryer J: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer 15; 68: 264-8, 1991.
8. Oster MW, Gray R, Panasci L and Perry MC: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 57: 29-33, 1986.
9. Wiggans RG, Woolley PV, Macdonald JS, Smythe T, Ueno W and Schein PS: Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41: 387-91, 1978.
10. Schnall SF and Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-8, 1996.
11. Cascinu S, Gasparini G, Catalano V, Silva RR, Pancera G, Morabito A, Giordani P, Gattuso D and Catalano G: A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 10: 1377-9, 1999.
12. Casper ES, Green MR, Kelsen DP,Heelan RT, Brown TD, Flombaum CD, Trahanowski B and Tarassoff PG: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994.
13. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Tarassoff PG, Brown TD, Casper ES, Storniolo AM and Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-53, 1996.
14. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma, Br J Surg 81: 882-5, 1994.
15. Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 6: 443-57, 1996.
16. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 20; 83: 288-91, 1991.
17. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22; 277: 665-7, 1979.
18. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 15; 51: 4845-52, 1991.
19. van Oosterom AT and Schrijvers D: Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 6: 356-68, 1995.
20. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clonet P, Lebecq A, Baille P, Lefresne-Soulas F, Blanc C and Armand JP: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36: 1016-25, 2000.
21. Schwartz GK and Casper ES: A phase II trial of doxorubicin HC1 Liposome Injection in patients with advanced pancreatic adenocarcinoma. Invest New Drugs'13: 77-82, 1995.
22. Vaage J, Donovan D, Uster P and Working P: Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 75: 482-6, 1997.
23. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1959.
24. Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA and Baker LH: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer 15; 71: 322-5, 1993.
25. Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y and Taguchi T: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 80: 438-43, 1999.
26. Allen TM, Hansen C, Martin F, Redeman C and Yau-Young A: Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1; 1066: 29-36, 1991.
27. Douglass HO: Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 40: 433-42, 1993.
28. Hui YF and Cortes JE: Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20: 1221-3, 2000.
29. Alberts DS and Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54 Suppl 4: 30-5,1997.
30. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Laugrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten EW, Huhn D and Riess H: A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer Ann Oncol 11: 1267-72, 2000.
31. Burch PA, Ghosh C, Schroeder G, Allmer C, Woodhouse CL, Goldberg RM, Addo F, Bernath AM, Tschetter LK, Windschitl HE and Cobau CD: Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial: Am J Clin Oncol 23: 534-7, 2000.
32. Ahmed S, Vaitkevicius VK, Zalupski MM, Zalupski MM, Du W, Arlauskas P, Gordon C, Kellogg C and Shields AF: Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study. Am J Clin Oncol 23; 420-4, 2000.